What’s Ahead for Sage Therapeutics, Inc. (SAGE) After Today’s Huge Increase?

February 25, 2018 - By Vivian Park

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.23, from 0.98 in 2017Q2. It increased, as 33 investors sold Sage Therapeutics, Inc. shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported.
Fernwood Inv Mgmt Limited Liability Company holds 0.33% or 8,400 shares in its portfolio. Tiaa Cref Investment Mngmt Limited Liability Com reported 120,514 shares. Art Ltd Company invested in 33,800 shares. Citadel Advisors Limited Liability Corporation reported 108,200 shares. 8,035 are held by Raymond James Advsrs Inc. Prudential Fincl stated it has 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Tudor Inv Corporation Et Al owns 4,815 shares for 0.01% of their portfolio. Ameritas Prtn stated it has 0.01% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Oak Ridge Limited invested in 736,709 shares. Eagle Asset Management Inc holds 0.23% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 627,031 shares. 6,814 were accumulated by Sg Americas Securities Ltd Liability Corp. Alliancebernstein Limited Partnership stated it has 604,219 shares or 0.03% of all its holdings. Lord Abbett And Ltd reported 0.05% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 57,563 were reported by Morgan Stanley. Moreover, Westpac Banking has 0.06% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 42,809 shares.

Since December 14, 2017, it had 0 buys, and 2 sales for $17.36 million activity. The insider Robichaud Albert sold 60,000 shares worth $9.57 million.

The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) is a huge mover today! The stock increased 5.63% or $8.75 during the last trading session, reaching $164.15. About 761,408 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 25, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.
The move comes after 8 months positive chart setup for the $7.47 billion company. It was reported on Feb, 25 by Barchart.com. We have $174.00 PT which if reached, will make NASDAQ:SAGE worth $448.20 million more.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. RBC Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, November 9. RBC Capital Markets has “Buy” rating and $145.0 target. The firm earned “Strong Buy” rating on Wednesday, December 14 by Raymond James. On Thursday, November 9 the stock rating was maintained by Cowen & Co with “Buy”. Leerink Swann maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, September 12 with “Buy” rating. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, June 23. As per Friday, March 11, the company rating was initiated by Lake Street. The company was maintained on Thursday, September 14 by BMO Capital Markets. Needham maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Tuesday, September 12 with “Buy” rating. The company was maintained on Thursday, November 2 by Stifel Nicolaus. The rating was initiated by Stifel Nicolaus on Monday, November 14 with “Buy”.

More recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Businesswire.com which released: “Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial …” on February 22, 2018. Also Prnewswire.com published the news titled: “Stock Review for Biotech’s Investors — Sage Therapeutics, Sarepta …” on February 12, 2018. Nasdaq.com‘s news article titled: “Commit To Buy Sage Therapeutics At $130, Earn 13.4% Using Options” with publication date: January 31, 2018 was also an interesting one.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company has market cap of $7.47 billion. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD). It currently has negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: